| 摘要 |
<p>The present invention relates to process for the preparation of highly pure Lenalidomide (I). The invention also relates to crystalline Form-SL obtained by the process of the present invention, the said Form-SL being substantially pure and characterized by X-ray powder diffraction pattern comprising of atleast seven peaks selected from 7.061, 12.860, 6.531, 18.698, 27.925, 33.212, 34.187, 35.253, 35.921 and 38.765 ± 0.1 °2θ; a single un-split °2θ peak at 7.813± 0.1 °2θ; and a three-way-split °2θ peak at 20.467 ± 0.1 °2θ. The invention further relates to pharmaceutical compositions comprising crystalline Form-SL of Lenalidomide, which may be useful for the treatment of cancer.</p> |
